Keysight Technologies Stock Gains After-Hours On Solid Q4 Earnings

Keysight Technologies (NYSE: KEYS) shares are trading higher in Monday's after-hours session after the company reported better-than-expected fourth-quarter financial results.

Keysight Technologies (NYSE:KEYS) shares are trading higher in Monday’s after-hours session after the company reported better-than-expected fourth-quarter financial results. Here’s a summary of the details.

What To Know: Keysight Technologies reported quarterly earnings of $1.99 per share, exceeding The Street’s estimate of $1.87, a 7.01% decrease over earnings of $2.14 per share from the same period last year.

Revenue clocked in at $1.31 billion which beat the analyst consensus estimate of $1.30 billion, a 9.22% decrease over sales of $1.44 billion the same period last year.

Additionally, cash flow from operations was $378 million, compared with $398 million last year. Free cash flow was $340 million, compared with $340 million in the same period of 2022.

The company sees first-quarter earnings between $1.53 and $1.59 per share, versus the $1.67 estimate, and revenue between $1.235 billion and $1.255 billion, versus the $1.24 billion estimate.

“Keysight delivered solid fourth quarter results and finished the year with record revenue, gross margin, and operating margin,” said Satish Dhanasekaran, Keysight’s President and CEO. “In what remains a challenging macro environment, our strategic customer engagement is high, and we are continuing to capitalize on opportunities across a broad and diverse set of end markets, positioning us well for an eventual recovery.”

Related Link: Why GD Culture Group Stock Popped Today

KEYS Price Action: Shares of KEYS were up 1.67% at $137.21 in the after-hours session at the time of publication, according to Benzinga Pro. 

Image by Pexels from Pixabay

Total
0
Shares
Related Posts
Read More

Theriva Biologics To Discuss The Trial Design For VIRAGE – A Phase 2b Clinical Study Of Systemically Administered VCN-01 In Combination With Chemotherapy In Pancreatic Ductal Adenocarcinoma At The 2024 ASCO Annual Meeting

Theriva™ Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that, based on the strength

TOVX

Read More

Hoth Therapeutics And 3 Other Stocks Under $3 Insiders Are Aggressively Buying

The Dow Jones jumped by around 197 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

BTTX